Denali Therapeutics Inc (DNLI)

$20.17 +0.42 (2.13%)
Market Cap 3.20B
Revenue (ttm) 0.00
Net Income (ttm) -512.54M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,892,100
Avg Vol 1,667,792
Day's Range N/A - N/A
Shares Out 158.59M
Stochastic %K 43%
Beta 1.02
Analysts Strong Sell
Price Target $32.93

Company Profile

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement thera...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 866 8547
Address:
161 Oyster Point Boulevard, South San Francisco, United States
PatienceisGrace
PatienceisGrace Mar. 20 at 12:47 PM
$DNLI $RCKT responding to this comment: Key Recent Single-Arm Study Approvals Waskyra (December 2025): Approved to treat Wiskott-Aldrich Syndrome based on two open-label, single-arm studies and an expanded access program. Sevabertinib (Hyrnuo) (November 2025): Granted accelerated approval for patients with HER2-mutated locally advanced or metastatic non-squamous NSCLC, supported by single-arm data. Papzimeos (September 2025): Approved for recurrent respiratory papillomatosis (RRP), based on a single-arm, open-label Phase 1/2 study that prioritized the percentage of patients needing no surgeries post-treatment. ANKTIVA (August 2024): Approved for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) based on a single-arm study of 88 patients. JenaValve Trilogy (March 2026): Received approval for high-risk aortic regurgitation based on the single-arm Align-AR study.
2 · Reply
Smellmahass
Smellmahass Mar. 20 at 7:47 AM
$DNLI This and $RCKT. They only use single arm so why would fda approve them? Fda declined rgnx and atra based on being single arm right?
2 · Reply
BullDonald
BullDonald Mar. 19 at 4:00 PM
$DNLI Yesterday was a sell everything market. Everything is going to shit. am done for the Year almost. Lets go already. give me a boost. This War may hurt every ticker soon.
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Mar. 19 at 3:14 PM
$BIIB $CELC $DNLI $TVTX —->pdufa tomorrow RYTM!
0 · Reply
DoctrBenway
DoctrBenway Mar. 19 at 2:13 PM
$DNLI For want of more capital a prime adding opportunity is missed. 🥲
0 · Reply
onlyGreenPlz
onlyGreenPlz Mar. 19 at 4:34 AM
$DNLI Bullish pennant forming. Breakout?
0 · Reply
BullDonald
BullDonald Mar. 17 at 6:28 PM
$DNLI Call summary (Inference) > discussion on Tivi - enthusiasm in the voice. > Good engagement with the FDA. confidence on the DATA. > Mis calculation issues solved, no Data issue. > Value proposition is huge. > label prediction : not yet fully prepared. NO clear answer > No finalized pricing Yet. > Pompeii, 2 Alzheimer - 3 pipelines will be added this year. > Bla bla bla on different diseases > preparation for the Launch ( Positive about the Approval ) I am loaded to the tits. LFG🚀
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Mar. 16 at 8:24 PM
$TVTX $BIIB $CELC $DNLI ALL WINNERS. GET IN WHILE YOU CAN FOLKS
0 · Reply
BullDonald
BullDonald Mar. 16 at 4:40 PM
$DNLI Ladies and Gentlemen Hop IN we are going to the MOON 🚀
0 · Reply
BullDonald
BullDonald Mar. 12 at 4:51 PM
$DNLI Cant have enough. Added another 2K around 20. LFG 🚀
0 · Reply
Latest News on DNLI
Denali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Virtual CNS Forum Transcript

Mar 20, 2026, 8:22 PM EDT - 1 day ago

Denali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Virtual CNS Forum Transcript

Denali Therapeutics Inc. (DNLI) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 6, 2026, 3:55 PM EST - 15 days ago

Denali Therapeutics Inc. (DNLI) Presents at TD Cowen 46th Annual Health Care Conference Transcript

FDA reversals leave investors worrying about the fates of other experimental drugs

Mar 6, 2026, 11:33 AM EST - 15 days ago

FDA reversals leave investors worrying about the fates of other experimental drugs

MRNA RGNX WVE

Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Feb 26, 2026, 4:01 PM EST - 23 days ago

Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Denali Therapeutics Inc. (DNLI) Shareholder/Analyst Call Transcript

Feb 6, 2026, 4:14 PM EST - 6 weeks ago

Denali Therapeutics Inc. (DNLI) Shareholder/Analyst Call Transcript

Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™

Feb 5, 2026, 2:00 PM EST - 6 weeks ago

Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™

Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™

Feb 2, 2026, 8:00 AM EST - 6 weeks ago

Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™

Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™

Jan 29, 2026, 4:00 PM EST - 7 weeks ago

Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™

Denali Therapeutics Inc. (DNLI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 12:45 AM EST - 2 months ago

Denali Therapeutics Inc. (DNLI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics' Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)

Dec 30, 2025, 8:00 AM EST - 2 months ago

The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics' Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)

Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment

Dec 10, 2025, 2:47 PM EST - 3 months ago

Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment

Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Dec 10, 2025, 12:14 AM EST - 3 months ago

Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

Dec 9, 2025, 4:01 PM EST - 3 months ago

Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

Denali Therapeutics Inc. (DNLI) Analyst/Investor Day Transcript

Dec 5, 2025, 2:58 AM EST - 3 months ago

Denali Therapeutics Inc. (DNLI) Analyst/Investor Day Transcript

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

Dec 4, 2025, 7:00 AM EST - 3 months ago

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

RPRX

Denali: Regulatory Delay Is A Strategic Opportunity

Dec 2, 2025, 8:09 AM EST - 3 months ago

Denali: Regulatory Delay Is A Strategic Opportunity

Denali Therapeutics Inc. (DNLI) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 22, 2025, 3:03 AM EST - 4 months ago

Denali Therapeutics Inc. (DNLI) Presents at Jefferies London Healthcare Conference 2025 Transcript

Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 6, 2025, 4:01 PM EST - 4 months ago

Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

FDA Delays Decision Date For Denali Therapeutics' Lead Drug Candidate

Oct 14, 2025, 2:43 PM EDT - 5 months ago

FDA Delays Decision Date For Denali Therapeutics' Lead Drug Candidate

Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)

Oct 13, 2025, 4:01 PM EDT - 5 months ago

Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)

Denali Therapeutics Inc. (DNLI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 2:31 AM EDT - 6 months ago

Denali Therapeutics Inc. (DNLI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

The Best Small-Cap Stocks to Buy Now

Aug 12, 2025, 9:47 AM EDT - 7 months ago

The Best Small-Cap Stocks to Buy Now

KYMR WAY

Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 11, 2025, 4:01 PM EDT - 7 months ago

Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)

Jul 7, 2025, 8:00 AM EDT - 9 months ago

Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)

Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

May 6, 2025, 4:01 PM EDT - 11 months ago

Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

Biotech stocks have been hit hard. Why they're a great value now.

Mar 27, 2025, 7:40 AM EDT - 1 year ago

Biotech stocks have been hit hard. Why they're a great value now.

PFE BHVN GPCR INSM MRK SWTX

Denali Therapeutics: Vast Pipeline, First Approval Up Ahead

Mar 20, 2025, 2:16 PM EDT - 1 year ago

Denali Therapeutics: Vast Pipeline, First Approval Up Ahead

Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Feb 27, 2025, 4:01 PM EST - 1 year ago

Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

Feb 6, 2025, 11:42 AM EST - 1 year ago

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

Why Is Denali Therapeutics Stock Trading Higher On Wednesday?

Jan 15, 2025, 2:26 PM EST - 1 year ago

Why Is Denali Therapeutics Stock Trading Higher On Wednesday?

Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains

Jan 9, 2025, 3:56 PM EST - 1 year ago

Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains

Denali Therapeutics ALS drug fails in mid-stage trial

Jan 6, 2025, 4:43 PM EST - 1 year ago

Denali Therapeutics ALS drug fails in mid-stage trial

Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

Jan 6, 2025, 4:30 PM EST - 1 year ago

Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic

Jan 3, 2025, 1:08 PM EST - 1 year ago

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic

Denali Has A Neurodegenerative Edge Despite Market Skepticism

Nov 16, 2024, 8:56 AM EST - 1 year ago

Denali Has A Neurodegenerative Edge Despite Market Skepticism

Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 6, 2024, 4:01 PM EST - 1 year ago

Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)

Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology

Aug 19, 2024, 10:55 PM EDT - 1 year ago

Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology

Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration

Aug 14, 2024, 2:00 PM EDT - 1 year ago

Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration

Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 1, 2024, 6:45 AM EDT - 1 year ago

Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies

Jun 3, 2024, 8:00 AM EDT - 1 year ago

Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies

Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data

May 13, 2024, 12:30 PM EDT - 2 years ago

Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data

Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

May 7, 2024, 4:01 PM EDT - 2 years ago

Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

May 1, 2024, 8:00 AM EDT - 2 years ago

Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

Denali: Leveraging Transport Vehicle Technology For Neurological Gains

Mar 6, 2024, 10:05 PM EST - 2 years ago

Denali: Leveraging Transport Vehicle Technology For Neurological Gains

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Feb 27, 2024, 8:05 AM EST - 2 years ago

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Denali Therapeutics Announces $500 million Private Placement Equity Financing

Feb 27, 2024, 8:00 AM EST - 2 years ago

Denali Therapeutics Announces $500 million Private Placement Equity Financing

Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™

Feb 7, 2024, 8:00 AM EST - 2 years ago

Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™

Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™

Feb 1, 2024, 8:00 AM EST - 2 years ago

Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™

PatienceisGrace
PatienceisGrace Mar. 20 at 12:47 PM
$DNLI $RCKT responding to this comment: Key Recent Single-Arm Study Approvals Waskyra (December 2025): Approved to treat Wiskott-Aldrich Syndrome based on two open-label, single-arm studies and an expanded access program. Sevabertinib (Hyrnuo) (November 2025): Granted accelerated approval for patients with HER2-mutated locally advanced or metastatic non-squamous NSCLC, supported by single-arm data. Papzimeos (September 2025): Approved for recurrent respiratory papillomatosis (RRP), based on a single-arm, open-label Phase 1/2 study that prioritized the percentage of patients needing no surgeries post-treatment. ANKTIVA (August 2024): Approved for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) based on a single-arm study of 88 patients. JenaValve Trilogy (March 2026): Received approval for high-risk aortic regurgitation based on the single-arm Align-AR study.
2 · Reply
Smellmahass
Smellmahass Mar. 20 at 7:47 AM
$DNLI This and $RCKT. They only use single arm so why would fda approve them? Fda declined rgnx and atra based on being single arm right?
2 · Reply
BullDonald
BullDonald Mar. 19 at 4:00 PM
$DNLI Yesterday was a sell everything market. Everything is going to shit. am done for the Year almost. Lets go already. give me a boost. This War may hurt every ticker soon.
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Mar. 19 at 3:14 PM
$BIIB $CELC $DNLI $TVTX —->pdufa tomorrow RYTM!
0 · Reply
DoctrBenway
DoctrBenway Mar. 19 at 2:13 PM
$DNLI For want of more capital a prime adding opportunity is missed. 🥲
0 · Reply
onlyGreenPlz
onlyGreenPlz Mar. 19 at 4:34 AM
$DNLI Bullish pennant forming. Breakout?
0 · Reply
BullDonald
BullDonald Mar. 17 at 6:28 PM
$DNLI Call summary (Inference) > discussion on Tivi - enthusiasm in the voice. > Good engagement with the FDA. confidence on the DATA. > Mis calculation issues solved, no Data issue. > Value proposition is huge. > label prediction : not yet fully prepared. NO clear answer > No finalized pricing Yet. > Pompeii, 2 Alzheimer - 3 pipelines will be added this year. > Bla bla bla on different diseases > preparation for the Launch ( Positive about the Approval ) I am loaded to the tits. LFG🚀
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Mar. 16 at 8:24 PM
$TVTX $BIIB $CELC $DNLI ALL WINNERS. GET IN WHILE YOU CAN FOLKS
0 · Reply
BullDonald
BullDonald Mar. 16 at 4:40 PM
$DNLI Ladies and Gentlemen Hop IN we are going to the MOON 🚀
0 · Reply
BullDonald
BullDonald Mar. 12 at 4:51 PM
$DNLI Cant have enough. Added another 2K around 20. LFG 🚀
0 · Reply
Drumpito
Drumpito Mar. 12 at 3:01 PM
$DNLI This will be Huuuuuuuge !! I am In at 20.
0 · Reply
BullDonald
BullDonald Mar. 12 at 1:56 PM
$DNLI Added 5K more shares. Averaged up. Loaded to the tits. LFG 🚀
0 · Reply
ZacksResearch
ZacksResearch Mar. 11 at 4:23 PM
$DNLI just ripped 11.8% in a month — but the real catalyst is still ahead. Investors are watching an April 5, 2026 FDA decision on tividenofusp alfa for Hunter syndrome, which could be a major growth driver and is clearly fueling the recent momentum. 👀 Big biotech catalysts can move fast — see the full setup before the decision 👉 https://www.zacks.com/stock/news/2882427/denali-gains-118-in-a-month-buy-sell-or-hold-the-stock?cid=sm-stocktwits-2-2882427-teaser-36991&ADID=SYND_STOCKTWITS_TWEET_2_2882427_TEASER_36991
0 · Reply
ZacksResearch
ZacksResearch Mar. 11 at 3:23 PM
$DNLI surges 11.8% in a month — what’s fueling the rally? 🚀 Investor optimism is high for the potential approval of tividenofusp alfa for Hunter syndrome, with a key FDA decision expected on April 5, 2026. Positive Breakthrough Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease designations underscore the drug's potential. 📈 See what makes the investment case strong for DNLI 👉 https://www.zacks.com/stock/news/2882427/denali-gains-118-in-a-month-buy-sell-or-hold-the-stock?cid=sm-stocktwits-2-2882427-body-36992&ADID=SYND_STOCKTWITS_TWEET_2_2882427_BODY_36992
0 · Reply
BullDonald
BullDonald Mar. 11 at 2:20 PM
$DNLI Order Placed ! Fill it . I need more.
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Mar. 10 at 6:08 PM
$DNLI LETS GO
1 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Mar. 10 at 5:09 PM
$DNLI $30 stock if fda approves Hunter syndrome indication
0 · Reply
NorthStarStats
NorthStarStats Mar. 10 at 2:30 AM
Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. $PYXS Score: 95.00 | >350% implied upside|Earnings, $AVGO Score 95.00 |100B+ in AI chip revenue expected, $GHRS Score: 95.00 |Solid Cash Runway| $42 upgrade, $DNLI Score: 95.00 |PDUFA tividenofusp alfa April 5, $LYV Score 73.00 |DOJ Setlmnt|Venue Nation Expansion
0 · Reply
BullDonald
BullDonald Mar. 9 at 7:41 PM
$DNLI Call started !
0 · Reply
Doozio
Doozio Mar. 9 at 3:34 PM
chop chop huckleberries wen the DAWN of a 🧠👀 became $DNLI of da 🐑 during 🐒🍌🧠⏰♾️
0 · Reply
BullDonald
BullDonald Mar. 7 at 1:51 PM
$DNLI - 80%+ institution ownership, - Big Pharma backing the pipelines, - The sentiment it Optimistic for the approval. - Low volume fluctuation caused by the Retail swinging it for a dollar or two. - Strong support level is 18. Should Bounce hard after shaking the paper hands. If it tests 18, I may add some to my position.🚀
0 · Reply
dgbio
dgbio Mar. 7 at 2:02 AM
$DNLI Prasad is fired again
0 · Reply